Connect with us

Technology

Beckman Coulter Diagnostics Expands Alzheimer’s Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay

Published

on

CE-marked Access p-Tau217 blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline across Europe

Brain Derived pTau217 RUO assay selectively detects brain-derived pTau217 unlocking new neurodegenerative insights through high-specificity research of amyloid and tau pathology

Powered by the DxI 9000 Immunoassay Analyzer, this expanding portfolio enables laboratories to
provide diverse testing capabilities within a single, high-throughput, high sensitivity solution

BREA, Calif., July 7, 2026 /PRNewswire/ — Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline. The company also introduced its high-specificity Access BD-pTau217 Research Use Only (RUO) assay at the Alzheimer’s Association International Conference (AAIC) 2026 in London.

The CE Mark represents a significant milestone in expanding access to blood-based p-Tau217 testing in Europe and additional CE-recognizing markets, supporting laboratories and clinicians with a scalable, automated solution. Building on this clinical progress, the newly launched RUO assay is designed to further advance research into disease biology. Both assays are enabled by the DxI 9000 Immunoassay Analyzer, ensuring laboratories can efficiently manage clinical and research tests on a single high-precision analyzer.

Scaling Access to Alzheimer’s Disease Blood Testing with CE-Marked, Automated p-Tau217 Assay

The new CE Marked assay measures phosphorylated tau (p-Tau217), a well-established biomarker associated with Alzheimer’s disease, enabling scalable assessment in routine clinical settings. Blood-based approaches can complement existing diagnostic pathways by offering a more accessible, operationally scalable method for evaluating Alzheimer’s-related pathology within laboratory workflows.

“Our CE-marked Access p-Tau217 assay brings a well-established Alzheimer’s biomarker into routine clinical workflows, enabling laboratories to scale blood-based evaluation of disease pathology more efficiently,” said Dr. Chris Bird, Chief Medical Officer at Beckman Coulter Diagnostics. “By making testing more accessible and operationally scalable, it helps integrate biomarker-based assessment into everyday clinical practice.”

Beckman Coulter Diagnostics developed the Access p‑Tau217 assay using AlzPath’s antibody, cited in more than 200 peer‑reviewed publications, underscoring strong scientific validation. As demand for Alzheimer’s disease diagnostics grows, blood‑based testing will play an increasingly important role in enabling consistent evaluation across clinical settings. This milestone marks the translation of validated biomarker science into Beckman Coulter’s first clinical, blood‑based assay for amyloid pathology in patients with signs and symptoms of cognitive decline, accelerating the path from research insight to real‑world use.

Introducing High-Specificity Brain-Derived pTau217 Assay for Research Use

In addition to the CE-marked IVD assay, Beckman Coulter Diagnostics is introducing its Access BD-pTau217 RUO assay, designed to selectively detect the short form (or low molecular weight) pTau217 in blood samples using the DxI 9000 Analyzer. By targeting the short form of pTau217 originating in the brain, the new research assay is designed to enhance biological specificity and provide precise characterization of central nervous system phosphorylated Tau217 signals in blood.

“By focusing on brain-derived pTau217, this assay is designed to deliver a higher level of biological specificity, helping researchers more precisely identify tau pathology in blood most relevant to their studies,” said Dr. Jeremiah Hinson, Chief Scientific Officer for Neurodegenerative Diseases at Danaher . “This increased specificity can bolster confidence in studying Alzheimer’s disease staging and support new insights into the biological inflection points that define how the disease evolves.”

Early research findings suggest that higher biological specificity may help improve interpretability of biomarker detection in complex research datasets and support clearer differentiation of tau-related pathology in Alzheimer’s disease.

“In the AIBL Study of Ageing, plasma pTau217 demonstrated strong performance as a blood‑based marker of Alzheimer’s pathology,” said James Doecke, PhD, Principal Research Scientist, Commonwealth Scientific and Industrial Research Organisation and the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. “When evaluated alongside amyloid and tau PET imaging, brain‑derived pTau217 showed additional biological specificity, particularly for research focused on tau‑related staging. These findings reinforce the role of pTau217 as a cornerstone biomarker while highlighting the potential value of higher biological specificity for improving clarity in Alzheimer’s disease research.”

Advancing Alzheimer’s Disease Testing Through the DxI 9000 Immunoassay System

Beckman Coulter Diagnostics is advancing its Alzheimer’s disease portfolio on the DxI 9000 Analyzer, a highly sensitive, scalable platform designed to detect low-abundance biomarkers with consistency. By enabling both the CE-marked Access p-Tau217 assay and the Access BD-pTau217 (RUO), as well as existing Access GFAP (RUO), Access BD-Tau (RUO), Access NfL (RUO), Access Beta-Amyloid 1-42 (RUO) and Access apoE ε4 (RUO) assays to run on a common platform, laboratories can integrate diverse testing capabilities within a consistent, high-throughput workflow.

“High-sensitivity detection, robust assays, and operational scalability are critical as blood-based biomarkers become more widely adopted,” said Dr. Nick Culshaw, Vice President and Managing Director, Clinical Chemistry and Immunoassay Business at Beckman Coulter Diagnostics. “By anchoring our Alzheimer’s disease portfolio on the DxI 9000 Analyzer, we are enabling laboratories to access an expanding set of biomarker insights, from clinical assessment to research applications, within a single system.”

The DxI 9000 Analyzer combines analytical sensitivity with operational flexibility, allowing laboratories to support a growing range of biomarker applications, from routine clinical evaluation to advanced research into disease biology, without compromising performance or efficiency. This unified platform approach helps ensure consistency in assay execution while enabling expansion into emerging markers across neurodegenerative diseases as scientific understanding evolves.

Beckman Coulter Diagnostics at AAIC 2026

At AAIC 2026 in London, Beckman Coulter Diagnostics will highlight new data advancing blood-based testing for Alzheimer’s disease through a focused program of scientific presentations and expert engagement.

The company will present five posters on pTau217 and novel biomarker approaches, including data demonstrating improved detection of Alzheimer’s pathology and enhanced performance using biomarker ratios and next-generation assays. Featured research spans clinical utility, disease staging and assay innovation, as well as late-breaker findings on pTau217/Aβ42 and BD‑Tau ratio approaches.

Key on-site engagements include:

Enabling Alzheimer’s Biological Staging with Blood Based Biomarkers, featuring James Doecke, PhD, and Charbel Abou-Diwan, PhD, Senior Director, Medical & Scientific Affairs, Beckman Coulter Diagnostics, July 13, 10:30–11:00 AMImproving real-world representation in Alzheimer’s disease research and treatment, Opening remarks by Jeremiah Hinson, M.D., Ph.D., followed by Sid E. O’Bryant, Ph.D.; Suzanne Craft, Ph.D.; Carlos Cruchaga, Ph.D.; Michelle Mielke, Ph.D.; Charlotte Teunissen, Ph.D.; and Michael Weiner, M.D. July 13, 12:30–1:45 PM 

Attendees can also visit the Beckman Coulter Diagnostics booth #921 to connect with experts and explore how high-throughput immunoassay platforms are supporting scalable adoption of blood-based biomarker testing.

About Beckman Coulter. Inc.

Beckman Coulter Diagnostics is a global leader in advanced diagnostics, helping laboratories transform insight into impact through science, technology, and collaboration. For more than 90 years, the company has challenged convention to elevate the role of the diagnostic laboratory, accelerating ideas from discovery to real world clinical outcomes. Guided by its mission to Relentlessly Reimagine Healthcare, One Diagnosis at a Time, Beckman Coulter Diagnostics delivers trusted solutions for complex clinical testing across hospitals, reference laboratories, and physician office settings worldwide, supported by an extensive clinical menu, scalable automation, actionable informatics, and lab performance optimization services. Part of Danaher, a global science and technology innovator, Beckman Coulter Diagnostics draws on a connected network of specialized companies—combining shared capabilities, scale, and expertise to help solve some of healthcare’s most complex challenges, together.  Headquartered in Brea, California, the company employs more than 11,000 associates globally.

Follow and connect with Beckman Coulter via LinkedIn, X, and Facebook

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

The Access p‑Tau217 assay is CE‑marked under IVDR (EU) 2017/746 (CE 2797)

© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. The Danaher trademark is a proprietary mark of Danaher Corporation. 3092-GBL-EN

View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-expands-alzheimers-portfolio-with-ce-marked-p-tau217-blood-test-and-new-high-specificity-research-assay-302818858.html

SOURCE Beckman Coulter Inc

Continue Reading

Technology

LexisNexis Coplogic Solutions Introduces Field Clarity for LexisNexis® Desk Officer Reporting System (DORS) at IACP 2026

Published

on

By

A new, modern DORS and Field Clarity, the First AI-Guided Smartphone Video Assistant, Enhances Community Experience and Helps Improve Evidence, Case Building

ORLANDO, Fla., Oct. 25, 2026 /PRNewswire/ — LexisNexis® Coplogic™ Solutions today announced its modernized LexisNexis® Desk Officer Reporting System (DORS) community online reporting solution and the addition of DORS with Field Clarity, an AI-guided video assistant designed to improve field documentation accuracy and enable faster resolution by law enforcement agencies (LEAs). Field Clarity is designed to help community members submit reports to their local LEAs using DORS via intuitive step-by-step instructions. A hands-on experience for DORS with Field Clarity will be available for demonstration during the 2026 International Association of Chiefs of Police (IACP) annual conference.

“Agencies generally look to strategic partners like us not just for technology, but also for relief, reinforcement, and credibility across three tightly connected challenges: public expectation, workforce strain and digital evidence overload,” said Jason LaRue, associate vice president, LexisNexis Coplogic Solutions. “Our modernized LexisNexis Desk Officer Reporting System (DORS) helps agencies improve officer safety along with community member experiences. Field Clarity strengthens video evidence quality and digital evidence management to reduce friction and alleviate strain on a challenged workforce.”

Key Highlights
Integrated into LexisNexis® Desk Officer Reporting System (DORS), Field Clarity is the first AI-Guided video assistant for community member online reporting that:

Transforms data capture from passive intake into intelligent, guided capture to help create more positive officer and civilian mobile-first experiencesDrives more accurate field documentation, evidence and case building to help with faster resolution and enhanced public safetyBenefits civilians submitting reports with intuitive, step-by-step instructions, almost like having a digital assistant with them in real timeBenefits officers by bringing video, photos and scanned data together for a clearer picture of an event without the need to track down additional details

How the DORS with Field Clarity Solution Works
DORS allows each law enforcement agency to collect information directly from civilians on more than 200 incident types based on the needs of their community. DORS and Field Clarity make the filing of an online report experience easier by guiding users intuitively through each step of the process on their smartphone device, similar to having a personal digital assistant. Instead of asking a driver, for example, to fill out forms and guess what’s needed, the Field Clarity conversational interface prompts them to scan their driver’s license, capture a VIN or record a short walkaround video explaining what happened during the incident, all while capturing the data necessary to complete the report.

For civilians, being able to easily film on-scene evidence means less confusion and need for reentries or follow-up by the sworn officer responsible for approving reports. For officers, the benefits include cleaner, more complete accident reports and less time spent requesting and gathering additional details. With reports fed directly into the agency’s Record Management System (RMS), law enforcement also benefits from more efficient workflows and stronger documented cases for their investigators. DORS is used by nearly 600 agencies in North America, saving agencies approximately 900,000 personnel hours and $90 million annually*

“Trust in law enforcement is built one interaction at a time. Every opportunity for a community member to engage with their police department matters, including something as routine as filing a report,” said Sarah E. Connolly, co-founder of Guardian Communications, FBI-LEEDA instructor and retired Baltimore Police lieutenant and PIO. “When technology makes that process easier, improves the quality of information collected and supports a more responsive agency, it has the potential to do more than improve efficiency. It can help strengthen the relationship between law enforcement and the communities they serve.”

LexisNexis Coplogic Solutions delivers solutions and capabilities that can create a clearer line of sight from the field to law enforcement leadership, strengthening the connection between daily operations, workforce support, data management and community trust. DORS with Field Clarity is available through LexisNexis® Command Center, a single access point to the LexisNexis Coplogic Solutions data and analytics solutions suite, including LexisNexis®  BuyCrash®, LexisNexis® eCrash and LexisNexis® eCitation solutions. Coplogic Solutions also offers Unified Performance Dashboards for crash and citation mapping and illustrated visualizations, which connect field data with contextual insight in a single, coherent view – so law enforcement leaders can better understand and more confidently explain to their communities not just what is happening in near-real time, but also why. 

To speak with Coplogic law enforcement experts about LexisNexis Desk Officer Reporting System (DORS) with Field Clarity and experience the solution firsthand, visit LexisNexis Coplogic Solutions at IACP Booth #941, October 24 – 27, 2026 in Orlando, Florida. To learn more, check out this video: LexisNexis® Desk Officer Reporting System (DORS).

About LexisNexis Risk Solutions
LexisNexis® Risk Solutions provides customers with information-based analytics and decision tools that combine public and industry-specific content with advanced technology and algorithms to assist them in evaluating and predicting risk and enhancing operational efficiency. Headquartered in metro Atlanta, Georgia, the company has offices throughout the world, serves customers in more than 190 countries and territories and is part of RELX. For more information, please visit LexisNexis Risk Solutions.

About LexisNexis Coplogic Solutions
LexisNexis® Coplogic™ Solutions is committed to meeting law enforcement agencies where they are on the road to saving more lives and helping take them where they want to be by delivering an innovative full suite of data sophistication solutions to create workflow efficiencies while delivering world-class crash and citation data and analytics visualizations through advanced technology. Our proven solutions, developed by and specifically for law enforcement, can help agencies operate more effectively, increase services to their communities and improve traffic and overall public safety through electronic, mobile-first authoring capabilities, web-based eCommerce solutions, analytics and more. For more information, please visit risk.lexisnexis.com/Coplogic.

Media Contacts: 
Chaz Abbott
LexisNexis Risk Solutions
chaz.abbott@lexisnexisrisk.com
+1 949.922.1167

*Based on a 2025 LexisNexis Coplogic Solutions internal study

View original content to download multimedia:https://www.prnewswire.com/news-releases/lexisnexis-coplogic-solutions-introduces-field-clarity-for-lexisnexis-desk-officer-reporting-system-dors-at-iacp-2026-302918694.html

SOURCE LexisNexis Risk Solutions

Continue Reading

Technology

World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang

Published

on

By

WENZHOU, China, Oct. 25, 2026 /PRNewswire/ — A news report from China Daily:

On October 24, the World Young Scientist Summit 2026 opened in Wenzhou, Zhejiang. The event is hosted by the China Association for Science and Technology (CAST), the Zhejiang Provincial People’s Government, and the World Association of Young Scientists. Nearly 800 representatives, including scientists, educators, and entrepreneurs from more than 60 countries and regions, are attending the summit.

With the theme “Gathering Talents Worldwide to Create a Better Future,” the summit’s annual agenda is “Global Youth Action in the AI Era: Building a Sustainable Future.” It aims to draw on the insights of young people around the world, deepen international sci-tech cooperation, and jointly address questions about young people, science, the world and the future.

Delivered keynote speeches respectively on education reform in the AI era, AI and processor chips, young women scientists’ participation in science, and quantum computing. They explored new opportunities for scientific research, talent cultivation, and international cooperation in the AI era.

This year’s summit placed greater emphasis on the growth needs of young scientists, with young talents under the age of 45 accounting for 88 percent of participants. It aimed to build a cluster of international journals, bring together young scientific talent, facilitate a batch of international collaborative projects and advance the application and commercialization of scientific and technological achievements. The summit released the Report on the Distribution and Mobility of Young Scientists in the Field of Embodied Intelligence, launched the World Young Scientist Summit Partner Journal Program and the 2026 World Young Scientist Innovation and Entrepreneurship Growth Support Program. It also published the “Young Scientist Pioneers 2035” list and announced the 2026 Sustainable Development Young Scientist Award. The awards were presented to four Chinese and foreign scientists.

In addition, the conference focused on fields such as future manufacturing, quantum information, embodied intelligence, brain-computer intelligence, environmental science, deep-sea resources, and life and health, and held 12 parallel forums. It also included the “Gravitation π” Future Technology and Concept Products Exhibition and Exchange, local thematic side events, and sci-tech and humanities study visits, further building an interdisciplinary, cross-regional and cross-sector platform for youth sci-tech exchange and cooperation.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/world-young-scientist-summit-2026-opens-in-wenzhou-zhejiang-302918767.html

SOURCE China Daily

Continue Reading

Technology

Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration

Published

on

By

Celebrities, athletes and creators came together for an action-packed night of gaming, immersive entertainment and exclusive experiences on Cosm’s massive Shared Reality Display. 

INGLEWOOD, Calif., Oct. 25, 2026 /PRNewswire/ — Monster Energy transformed Cosm Los Angeles into the ultimate gamer’s destination on Friday night as fans came together to celebrate the highly anticipated launch of Call of Duty®: Modern Warfare® 4 at an immersive event fueled by Monster Energy.

Set against Cosm’s spectacular 87-foot-diameter, 12K+ LED dome, the Monster Energy x Call of Duty celebration brought the action of one of gaming’s most anticipated franchises into the real world. Guests experienced live gameplay, special celebrity appearances, interactive activations, and real-life displays inspired by the game, including the Monster Energy Operator Skin, alongside a lineup of Polaris vehicles including the DAGOR, which is playable in Modern Warfare 4 – all in an electrifying atmosphere that blurred the lines between gaming and reality.

The event drew a guest list spanning entertainment, sports and gaming, including actors O’Shea Jackson Jr., Trevor Jackson and Khleo Thomas, who arrived by Slingshot, rapper Symba, social media star Lin Lamar (Pinkchyu), and Monster Energy UFC fighters Johnny Walker and Jalin Turner.

Guests lined up around the block for a jam-packed program, featuring a live edition of The Flank, hosted by ZooMaa and Ben Nissim, including an interview with Infinity Ward developer Jacky Reynolds and the reveal of the CDL Launch Invitational groups. Fans also got a closer look at Modern Warfare 4’s DMZ mode during a gameplay showcase led by Infinity Ward game designer Roman Spazafumo.

The gaming action continued with artists, athletes and gaming creators, including Jericho, Jaybroski, Tyler Rizzi, Johnny Walker and LAFC’s Denis Bouanga, facing off in two-versus-two matchups, while fans tested their own skills in king-of-the-hill rounds. Monster Energy’s skate team also took to the virtual battlefield, swapping their boards for controllers, with Ishod Wair, Filipe Mota and Elliot Sloan going head-to-head in a Modern Warfare 4 showdown.

“With Call of Duty, we’re always looking for ways to push the experience beyond the screen,” said Jordi Gayola, CMO of the Americas at Monster Energy. “Bringing this launch to Cosm gave us an incredible opportunity to put fans, athletes and creators right in the middle of the action. It’s about bringing our worlds together and creating the kind of unforgettable experience that only Monster Energy can deliver.”

Beyond the main gameplay, fans enjoyed exclusive merchandise giveaways and immersive experiences, while the Modern Warfare 4-themed experience extended to the menu, which featured Korean-inspired dishes including kimchi mandu, Korean corn cheese nachos, and gochujang-glazed wings, alongside complimentary Monster Energy throughout the venue.

The launch also spotlighted Monster Energy’s ongoing Call of Duty promotional partnership, running through March 31, 2027. Fans can earn 15 minutes of Double XP per qualifying Monster Energy Original Green, Zero Sugar or Zero Ultra can, alongside exclusive in-game rewards, including a Large Decal, two weapon blueprints and two Operator Skins unlocked across the first five cans. The collaboration also extends beyond the game through four Monster Energy x Polaris vehicle sweepstakes at participating 7-Eleven, Hy-Vee, QuikTrip and RTG stores, with entry via retailer-specific QR codes in-store.

For more information on the Monster Energy x Call of Duty partnership, promotion and rewards, visit callofduty.monsterenergy.com.

Images from the Monster Energy Call of Duty®: Modern Warfare® 4 Launch Day are available HERE. 

Photo Credit: Randy Shropshire/Getty Images for Monster Energy.

About Monster Energy
Based in Corona, California, Monster Energy is a leading marketer of energy drinks and alternative beverages. Known for its connection to action sports, motorsports, music, gaming and athletes around the world, Monster Energy fuels the passions of its fans through products, partnerships and experiences that bring communities together. For more information, visit MonsterEnergy.com.

Media Contact:
press@monsterenergy.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/monster-energy-and-call-of-duty-take-over-cosm-los-angeles-for-immersive-modern-warfare-4-launch-celebration-302918764.html

SOURCE Monster Energy

Continue Reading

Trending